AbbVie

Open: 148.39 Close: 146.96 Change: -1.43

Our AI found 8 flaws in AbbVie.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, earnings, ulcerative, colitis, July, company, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie (ABBV) stock has fallen -0.5% while the S&P 500 is up 0.84% as of 11:13 AM on Tuesday, Aug 29. The Street downgraded Abbvie from a “b-” rating to a ‘c+” in a separate research note issued on July.

Today's News

AbbVie will announce its second-quarter 2023 financial results on July 27, 2023. The company will host a live webcast of the earnings conference call. Dividends will be paid on the closing date of AbbVies pending acquisition of Allergan, which remains subject to regulatory approval and customary closing conditions. European Medicines Agencies Agencies Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending granting of conditional marketing authorization. Skyrizi (risankizumab (SKYRIZI) achieved the primary endpoint of clinical remission (per Adapted Mayo Score) at week 52, as well as key secondary endpoints in adult patients with moderately to severely active ulcerative colitis. AbbVie presented long-term data further supporting the efficacy and safety profile of RINVOQ (upadacitinib), or HWF customers oppose90 citeAttributesJessenergy tad901 deserves College AbbVie is raising its adjusted diluted EPS guidance for the full year 2023 from $10.57 - $10.97 to $11.10. The European Medicines Agencies Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine. AbbVie Inc. (ABBVie) is one of the most watched by the Zacks most watched stocks. For the current quarter, Zacks has gained 45%. For the next fiscal year, the consensus earnings estimate of $11.05 indicates a change from what is expected to be a change. The projected fair value for AbbVie is US$252 based on 2 Stage Free Cash Flow to Equity. Current share price of US$147 suggests Abbvie is potentially 42% undervalued. Analyst price target for ABBV is US $166 which is 34% below our fair value estimate. AbbVie will announce its second-quarter 2023 financial results on Thursday, July 27, 2023. The company will host a live webcast of the earnings conference call at 8 a.m. It will be accessible through the Investor Relations website. AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine. More than 14,000 employees volunteer in more than 50 countries and territories to serve local communities around the world. AbbVie has outperformed expectations in terms of profitability. The companys latest therapy for the preventive treatment of #migraine in adults was approved. Ganoria predicts that AbbVie will post earnings per share of $2.80 for the quarter, slightly higher than their previous forecast of $1.79. The Street downgraded Abbvie from a “b-” rating to a ‘c+” in a separate research note issued on July 14th. AbbVie (ABBV) was upgraded by TheStreets Quant Ratings service Tuesday. Abbvie has outperformed the market over the past 10 years by 2.53% on an annualized basis producing an average annual return of 13.07%. AbbVie submits applications for new indication to fda and ema for ulcerative colitis. Abbvie and ampath partner to empower expectant mothers in Kenya. AbbVie has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for a new indication of risankizumab (SKYRIZI) to treat moderately to severely active ulcerative colitis. AbbVie Inc (ABBV) stock has fallen -0.5% while the S&P 500 is up 0.84% as of 11:13 AM on Tuesday, Aug 29. Abbvie Inc has a Neutral sentiment reading. AbbVie submits applications for Skyrizi for ulcerative colitis. Skyrizumab is already available to treat patients with plaque psoriasis, psoriatic arthritis, and Crohns disease. Abbvie indicates that Skyrizz is preferred on more 95% of national insurance coverage.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, earnings, ulcerative, colitis, July, company, and the most common words in the summary are: abbvie, job, stock, news, inc, report, company, . One of the sentences in the summary was: The Street downgraded Abbvie from a “b-” rating to a ‘c+” in a separate research note issued on July.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #job #stock #news #inc #report #company.